May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Development of a Bioerodible Insert for the Ocular Delivery of a Novel Next Generation Calcineurin Inhibitor
Author Affiliations & Notes
  • J. Kohn
    New Jersey Center for Biomaterials, Rutgers University, Piscataway, New Jersey
  • J. Khan
    New Jersey Center for Biomaterials, Rutgers University, Piscataway, New Jersey
  • C. Iovine
    New Jersey Center for Biomaterials, Rutgers University, Piscataway, New Jersey
  • P. Velagaleti
    Lux Biosciences, Inc., Jersey City, New Jersey
  • Footnotes
    Commercial Relationships  J. Kohn, Lux Biosciences, Inc., F; Lux Biosciences, Inc., P; J. Khan, Lux Biosciences, Inc., F; Lux Biosciences, Inc., P; C. Iovine, Lux Biosciences, Inc., F; Lux Biosciences, Inc., P; P. Velagaleti, Rutgers University, F; Rutgers University, P.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5007. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J. Kohn, J. Khan, C. Iovine, P. Velagaleti; Development of a Bioerodible Insert for the Ocular Delivery of a Novel Next Generation Calcineurin Inhibitor. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5007. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The local delivery of sustained, effective concentrations of immunosuppressive therapy that is safe, well-tolerated, and suitable for long-term use is a major need within the ophthalmic disease treatment community.

Methods: : The development of a small, implantable bioerodible drug delivery device appropriate for the treatment of various immune-based ophthalmic conditions is presented here. The new device is a composite matrix consisting of a resorbable thermoplastic terpolymer and a novel cyclic peptide calcineurin inhibitor (LX211/ISA247). LX211 (ISA247), as an oral formulation, is currently in Phase III development for the treatment of non-infectious, idiopathic uveitis.

Results: : In order to optimize the delivery system of this implantable device, various candidate matrix polymers were selected from a large, combinatorial library of bioerodible polyarylates and polycarbonates, based on desaminotyrosyltyrosine alkyl ester as the main dipeptide monomer component of the polymer chain. The suitability of the various polyarylate and polycarbonate compositions in this drug-eluting device was further characterized using the following measures: drug release kinetics, polymer molecular weight degradation, polymer mass loss by erosion, and water uptake. The overall device design parameters necessary for producing bioerodible ocular implants are presented here. Thus, an optimal sustained yet tunable drug release profile for a novel implantable ocular device was obtained by molecular engineering of the chemical composition and physical properties of the matrix polymer.

Conclusions: : The development of a bioerodible implant for the ocular delivery of a novel, next generation calcineurin inhibitor represents a new, hybrid mechanism of drug release that is capable of sustained peptide release from 6 to 24 months and has potential clinical implications for the treatment of immune-based ophthalmic conditions.

Keywords: immunomodulation/immunoregulation • uveitis-clinical/animal model • drug toxicity/drug effects 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×